Dr. Corey J. Langer from Abramson Cancer Center Discusses the JMEN Maintenance Pemetrexed Trial
OncLive TV
Dr. Donald McDonald from the UCSF Comprehensive Cancer Center on the Continued Understanding of Bevacizumab
Advertisement
Dr. Kemp Kernstine from University of Texas, Southwestern Medical Center Discusses Variation in Thoracic Surgery Outcomes
Dr. Hope S. Rugo from University of California, San Francisco on Proliferation as an Anti-Angiogenesis Marker
Joanna Morales from the Cancer Legal Resource Center on Common Cancer Related Legal Issues
Dr. Monica Morrow from Memorial Sloan-Kettering Cancer Center on the Z11 Trial Results Changing Practice
Advertisement
Dr. Corey J. Langer from Abramson Cancer Center on Assessing Patient Populations in Clinical Trials
Dr. Joyce A. O'Shaughnessy from the Baylor Sammons Cancer Center Describes the School of Breast Oncology
Dr. Gordon Mills from MD Anderson Cancer Center Explains the Vulnerability of Cancer Cells
Dr. Monica Morrow from Memorial Sloan-Kettering Cancer Center Describes the ACOSOG Z11 Trial
Dr. Heather Wakelee from Stanford Clinical Cancer Center Discusses Adjuvant Therapy Predictive Markers
Joanna Morales from the Cancer Legal Resource Center Explains Cancer Related Legal Issues
Dr. Gordon B. Mills from MD Anderson Cancer Center Discusses Shifts Towards Personalized Medicine
Dr. Michael Dixon from University of Edinburgh on Systems Biology Determining Therapy Combinations
Dr. Barbara Burtness from Fox Chase Cancer Center on the Head and Neck Symposium Design
Dr. Giorgio Scagliotti from the University of Turin in Italy on EGFR Targeted Therapy Survival Benefits
Dr. Barbara Burtness from Fox Chase Cancer Center Discusses the Upcoming Head and Neck Cancer Symposium
Dr. Matthew Ellis from Washington University, St Louis, Discusses Genome Forward Breast Cancer Treatment
Dr. Ken Y. Yoneda from UC Davis Cancer Center Discusses Pulmonary Nodules
Dr. Donald McDonald from UCSF Comprehensive Cancer Center Explains Approved Angiogenesis Inhibitors
Dr. Heather Wakelee from Stanford Clinical Cancer Center on Explaining Adjuvant Therapy to Patients
Dr. Debu Tripathy from Norris Comprehensive Cancer Center Discusses Breast Carcinoma Heterogeneity
Dr. Tianhong Li from University of California Davis Cancer Center Describes the Future of Lung Cancer Therapy
Dr. Hope Rugo from UCSF Cancer Center on VEGF-A as an Avastin Response Predictor
Dr. Giorgio Scagliotti from University of Turin Discusses EGFR Mutations in non-small cell lung cancer
Dr. J. Michael Dixon from University of Edinburgh on Letrozole Used in Combination With Pathway Inhibitors
Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on the Future of Triple Negative Breast Cancer Treatment
Dr. Matthew Ellis from Washington University on Anticipated ER-positive/HER2-negative Breast Cancer Paradigms
Dr. Heather Wakelee from Stanford Clinical Cancer Center on Adjuvant Therapy in Elderly NSCLC Patients
Dr. Giorgio Scagliotti from the University of Turin on Tailored Treatment and the Cancer Genome
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
4
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
5